BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27891827)

  • 1. GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Yang L; Wen XM; Guo H; Yang J; Deng ZQ; Qian J
    Cancer Med; 2017 Jan; 6(1):267-274. PubMed ID: 27891827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX7 methylation is an independent prognostic factor in myelodysplastic syndromes.
    Xu ZJ; Tang CY; Zhou JD; Ma JC; Wen XM; Deng ZQ; Leng JY; Qiu ZY; Qian J; Lin J
    Pathol Res Pract; 2019 Feb; 215(2):322-328. PubMed ID: 30554866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes.
    Zhou JD; Zhang TJ; Xu ZJ; Deng ZQ; Gu Y; Ma JC; Wen XM; Leng JY; Lin J; Chen SN; Qian J
    Cell Death Dis; 2020 Nov; 11(11):997. PubMed ID: 33219204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
    Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
    Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPX3 promoter is methylated in chronic myeloid leukemia.
    Yao DM; Zhou JD; Zhang YY; Yang L; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
    Int J Clin Exp Pathol; 2015; 8(6):6450-7. PubMed ID: 26261521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
    Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
    Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
    J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
    Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
    Am J Cancer Res; 2015; 5(5):1786-94. PubMed ID: 26175946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.
    Gonçalves AC; Alves R; Baldeiras I; Cortesão E; Carda JP; Branco CC; Oliveiros B; Loureiro L; Pereira A; Nascimento Costa JM; Sarmento-Ribeiro AB; Mota-Vieira L
    Mol Carcinog; 2017 Jan; 56(1):130-148. PubMed ID: 26950655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
    Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
    Am J Cancer Res; 2015; 5(6):2047-55. PubMed ID: 26269763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of aberrant p73 promoter methylation in patients with myelodysplastic syndrome].
    Zhao YS; Yang R; Gu SC; Guo J; Zhang X; Wu LY; Li X; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):847-51. PubMed ID: 23384909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome.
    Zhao G; Li N; Li S; Wu W; Wang X; Gu J
    Int J Oncol; 2019 Feb; 54(2):491-504. PubMed ID: 30535457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypomethylation of MIR-378 5'-flanking region predicts poor survival in young patients with myelodysplastic syndrome.
    Wu DH; Zhu XW; Wen XM; Zhang YY; Ma JC; Yao DM; Zhou JD; Guo H; Wu PF; Zhang XL; Qiu HC; Lin J; Qian J
    Mol Genet Genomic Med; 2020 Jan; 8(1):e1067. PubMed ID: 31833222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
    Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
    Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
    BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
    Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
    J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
    Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
    Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome.
    Zhang YY; Zhou JD; Yang DQ; He PF; Yao DM; Qian Z; Yang J; Xu WR; Lin J; Qian J
    Clin Chem Lab Med; 2018 Feb; 56(3):485-491. PubMed ID: 29031013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.